TG THERAPEUTICS INC (NASDAQ:TGTX) reported its fourth quarter and full-year 2025 financial results, delivering revenue that largely met expectations but earnings per share that fell short of analyst forecasts. The company also provided a robust revenue outlook for its lead product, BRIUMVI, which appears to align with broader market expectations for the coming year. The initial market reaction, however, has been negative, with the stock trading down significantly in pre-market activity.
Earnings and Revenue Versus Estimates
The core financial metrics for Q4 2025 presented a mixed picture when held against Wall Street's expectations.
- Revenue: The company reported total revenue of $192.6 million for the quarter, narrowly missing the analyst consensus estimate of approximately $196.1 million. The vast majority of this revenue, $182.7 million, was attributed to U.S. net sales of its multiple sclerosis therapy, BRIUMVI.
- Earnings Per Share (EPS): The earnings miss was more pronounced. TG Therapeutics reported non-GAAP EPS of $0.14 for the quarter, which was substantially below the analyst estimate of $0.36.
This earnings shortfall is the most likely catalyst for the negative pre-market price movement. While revenue was essentially in line, the lower-than-expected profitability suggests higher costs or investments that impacted the bottom line, giving investors pause.
Market Reaction and Recent Performance
The immediate market response to the earnings release has been sharply negative. Ahead of the opening bell, shares of TG Therapeutics are indicated down approximately 7%. This drop stands in contrast to the stock's relatively flat performance over the past week and month, indicating the earnings report is a significant new data point driving investor sentiment.
The pre-market decline suggests the market is focusing more on the earnings miss and potentially the costs associated with the company's growth, rather than the solid top-line revenue or the forward guidance.
Company Outlook and Analyst Expectations
A key positive from the report was the company's raised financial guidance. Management now targets total global revenue for the full year 2026 in the range of approximately $875 million to $900 million. This outlook is primarily driven by continued growth expectations for BRIUMVI.
When compared to the broader analyst consensus, this company-provided range appears consistent. Analysts are currently estimating sales of approximately $917.3 million for TG Therapeutics in 2026. The company's guidance, while slightly more conservative at the midpoint, falls within a reasonable range of these external expectations, indicating management confidence is in step with market forecasts.
Summary of Key Announcements
Beyond the raw financial numbers, the press release highlighted several important developments for TG Therapeutics:
- Strong BRIUMVI Growth: Full-year 2025 U.S. net revenue for BRIUMVI reached $594.1 million, demonstrating significant commercial traction for the therapy since its launch.
- Raised Forward Guidance: The company proactively increased its total global revenue target for 2026 to the $875-$900 million range, underscoring management's bullish outlook on future growth.
- Financial Position: The report details the company's cash reserves and operational expenditures, providing context for its ability to fund continued commercialization and development efforts.
For a detailed breakdown of historical earnings, future estimates, and analyst projections, you can review the full data here.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer to buy or sell any security. Investing involves risk, including the potential loss of principal. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions.